Systematic evaluation of the pre-eclampsia drugs, dietary supplements and biologicals pipeline using target product profiles.

Humans Pregnancy Female Pre-Eclampsia / drug therapy Biological Products / therapeutic use Dietary Supplements Vitamin D Metformin / therapeutic use
Chloroquine Drug development Esomeprazole Hypertension L-Arginine Maternal medicine Metformin Pregnancy Sulfasalazine Vitamin D

Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
04 11 2022
Historique:
received: 09 05 2022
accepted: 26 09 2022
entrez: 4 11 2022
pubmed: 5 11 2022
medline: 8 11 2022
Statut: epublish

Résumé

The Accelerating Innovation for Mothers (AIM) project established a database of candidate medicines in research and development (R&D) between 2000 and 2021 for five pregnancy-related conditions, including pre-eclampsia. In parallel, we published target product profiles (TPPs) that describe optimal characteristics of medicines for use in preventing/treating pre-eclampsia. The study objective was to use systematic double screening and extraction to identify all candidate medicines being investigated for pre-eclampsia prevention/treatment and rank their potential based on the TPPs. Adis Insight, Pharmaprojects, WHO international clinical trials registry platform (ICTRP), PubMed and grant databases were searched (Jan-May 2021). The AIM database was screened for all candidates being investigated for pre-eclampsia. Candidates in clinical development were evaluated against nine prespecified criteria from TPPs identified as key for wide-scale implementation, and classified as high, medium or low potential based on matching to the TPPs. Preclinical candidates were categorised by product type, archetype and medicine subclass. The AIM database identified 153 candidates for pre-eclampsia. Of the 87 candidates in clinical development, seven were classified as high potential (prevention: esomeprazole, L-arginine, chloroquine, vitamin D and metformin; treatment: sulfasalazine and metformin) and eight as medium potential (prevention: probiotic lactobacilli, dalteparin, selenium and omega-3 fatty acid; treatment: sulforaphane, pravastatin, rosuvastatin and vitamin B3). Sixty-six candidates were in preclinical development, the most common being amino acid/peptides, siRNA-based medicines and polyphenols. This is a novel, evidence-informed approach to identifying promising candidates for pre-eclampsia prevention and treatment - a vital step in stimulating R&D of new medicines for pre-eclampsia suitable for real-world implementation.

Sections du résumé

BACKGROUND
The Accelerating Innovation for Mothers (AIM) project established a database of candidate medicines in research and development (R&D) between 2000 and 2021 for five pregnancy-related conditions, including pre-eclampsia. In parallel, we published target product profiles (TPPs) that describe optimal characteristics of medicines for use in preventing/treating pre-eclampsia. The study objective was to use systematic double screening and extraction to identify all candidate medicines being investigated for pre-eclampsia prevention/treatment and rank their potential based on the TPPs.
METHODS
Adis Insight, Pharmaprojects, WHO international clinical trials registry platform (ICTRP), PubMed and grant databases were searched (Jan-May 2021). The AIM database was screened for all candidates being investigated for pre-eclampsia. Candidates in clinical development were evaluated against nine prespecified criteria from TPPs identified as key for wide-scale implementation, and classified as high, medium or low potential based on matching to the TPPs. Preclinical candidates were categorised by product type, archetype and medicine subclass.
RESULTS
The AIM database identified 153 candidates for pre-eclampsia. Of the 87 candidates in clinical development, seven were classified as high potential (prevention: esomeprazole, L-arginine, chloroquine, vitamin D and metformin; treatment: sulfasalazine and metformin) and eight as medium potential (prevention: probiotic lactobacilli, dalteparin, selenium and omega-3 fatty acid; treatment: sulforaphane, pravastatin, rosuvastatin and vitamin B3). Sixty-six candidates were in preclinical development, the most common being amino acid/peptides, siRNA-based medicines and polyphenols.
CONCLUSIONS
This is a novel, evidence-informed approach to identifying promising candidates for pre-eclampsia prevention and treatment - a vital step in stimulating R&D of new medicines for pre-eclampsia suitable for real-world implementation.

Identifiants

DOI: 10.1186/s12916-022-02582-z PMID: 36329468 PMC: PMC9635102
pubmed: 36329468
doi: 10.1186/s12916-022-02582-z
pii: 10.1186/s12916-022-02582-z
pmc: PMC9635102
doi:

Substances chimiques

Biological Products 0
Vitamin D 1406-16-2
Metformin 9100L32L2N

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

393

Informations de copyright

© 2022. The Author(s).

Références

Placenta. 2020 Dec;102:10-16
pubmed: 32980138
Semin Perinatol. 2009 Jun;33(3):130-7
pubmed: 19464502
BJOG. 2020 Mar;127(4):478-488
pubmed: 31715077
N Engl J Med. 2019 Sep 12;381(11):1035-1045
pubmed: 31509674
Circ Res. 2019 Mar 29;124(7):1094-1112
pubmed: 30920918
Am J Obstet Gynecol. 2022 Feb;226(2S):S1157-S1170
pubmed: 32946849
Taiwan J Obstet Gynecol. 2010 Jun;49(2):181-7
pubmed: 20708525
PLoS Med. 2008 Jan 22;5(1):e22
pubmed: 18215109
J Thromb Haemost. 2009 Jan;7(1):58-64
pubmed: 19036070
BMJ. 2021 Sep 22;374:n2103
pubmed: 34551918
Nitric Oxide. 2018 Nov 1;80:37-44
pubmed: 30099096
Lancet Glob Health. 2014 Jun;2(6):e323-33
pubmed: 25103301
Thromb Haemost. 2016 Oct 28;116(5):868-878
pubmed: 27440387
Arch Public Health. 2021 Oct 27;79(1):187
pubmed: 34706763
J Hum Hypertens. 2014 Apr;28(4):230-5
pubmed: 24172291
Front Surg. 2015 Feb 26;2:7
pubmed: 25767802
J Nutr. 2021 May 11;151(5):1359
pubmed: 33974699
Int J Gynaecol Obstet. 2022 Jun;158 Suppl 1:31-39
pubmed: 35762804
Cochrane Database Syst Rev. 2019 Jul 26;7:CD008873
pubmed: 31348529
Lancet HIV. 2021 Jan;8(1):e42-e50
pubmed: 33271125
Eur J Obstet Gynecol Reprod Biol. 2013 Sep;170(1):1-7
pubmed: 23746796
BMJ. 2011 May 19;342:d2901
pubmed: 21596735
Lupus. 2021 Jun;30(7):1163-1174
pubmed: 33853420
BJOG. 2019 Aug;126(9):1157-1167
pubmed: 30576053
Nat Rev Drug Discov. 2019 Jun;18(6):421-446
pubmed: 30846871
BJOG. 2016 Dec;123(13):2076-2086
pubmed: 27006180
Taiwan J Obstet Gynecol. 2020 Jan;59(1):8-15
pubmed: 32039806
BMJ Open. 2019 Oct 17;9(10):e027493
pubmed: 31628121
Ultrasound Obstet Gynecol. 2008 Jan;31(1):55-64
pubmed: 18098350
Diabet Med. 2018 Feb;35(2):160-172
pubmed: 29044702
Nat Rev Nephrol. 2019 May;15(5):275-289
pubmed: 30792480
PLoS Med. 2016 Nov 1;13(11):e1002161
pubmed: 27802279
BMJ Glob Health. 2020 Feb 28;5(2):e002067
pubmed: 32181003
Global Health. 2014 Oct 29;10:72
pubmed: 25367638
Br J Nutr. 2015 Jan 28;113(2):249-58
pubmed: 25571960
Nutrients. 2022 Feb 27;14(5):
pubmed: 35267975

Auteurs

Annie R A McDougall (ARA)

Maternal, Child and Adolescent Health Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia. annie.mcdougall@burnet.edu.au.
ORCID: 0000-0003-1182-6679

Roxanne Hastie (R)

Department of Obstetrics and Gynaecology, University of Melbourne, Heidelberg, Australia.

Maya Goldstein (M)

Policy Cures Research, Sydney, Australia.

Andrew Tuttle (A)

Policy Cures Research, Sydney, Australia.

Stephen Tong (S)

Department of Obstetrics and Gynaecology, University of Melbourne, Heidelberg, Australia.

Anne Ammerdorffer (A)

Concept Foundation, Geneva, Switzerland.

A Metin Gülmezoglu (AM)

Concept Foundation, Geneva, Switzerland.

Joshua P Vogel (JP)

Maternal, Child and Adolescent Health Program, Burnet Institute, 85 Commercial Road, Melbourne, VIC, 3004, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Systematic evaluation of the pre-eclampsia...
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Systematic evaluation of the pre-eclampsia...
questionsmedicales.fr › Maladies urogénitales › Maladies de l'appareil urogénital féminin et complications de la grossesse › Complications de la grossesse › Pré-éclampsie › Systematic evaluation of the pre-eclampsia...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Systematic evaluation of the pre-eclampsia...
questionsmedicales.fr › Aliments et boissons › Aliments › Compléments alimentaires › Systematic evaluation of the pre-eclampsia...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Sécostéroïdes › Vitamine D › Systematic evaluation of the pre-eclampsia...
questionsmedicales.fr › Composés chimiques organiques › Amidines › Guanidines › Biguanides › Metformine › Systematic evaluation of the pre-eclampsia...